<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03079531</url>
  </required_header>
  <id_info>
    <org_study_id>e-protocol 38599</org_study_id>
    <nct_id>NCT03079531</nct_id>
  </id_info>
  <brief_title>Open Label Study to Assess the Effect of Secukinumab in Moderate to Severe Papulopustular Rosacea</brief_title>
  <official_title>An Open Label Phase 1b Study of Secukinumab in Patients With Moderate to Severe Papulopustular Rosacea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anne Chang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to determine whether secukinumab is a potential therapy for those with
      papulopustular rosacea. We will observe whether this drug decreases the size and/or amount
      and severity of the pustules of those who suffer from rosacea.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rosacea is a common inflammatory skin disease affecting up to 10% of adults. Despite this,
      the etiology of rosacea is unclear, although there may be a genetic predisposition (Chang et
      al., 2015). Currently, there is no cure. Rosacea can lead to scarring, itching, burning, and
      is associated with anxiety and depression (Moustafa et al., 2015), significantly affecting
      quality of life.

      Secukinumab is an antibody that binds to a protein (interleukin (IL)-17A) that is involved in
      inflammation. When IL-17A is bound to secukinumab, it cannot bind to its receptor, thereby
      inhibiting its ability to feed the inflammatory response. In clinical trials, secukinumab has
      been effective for moderate to severe psoriasis (Blauvelt et al., 2015). Recently, human data
      from all types of rosacea have shown Th1/Th17 polarization profile of the T-cell response,
      suggesting that anti-IL-17 therapy may be beneficial for rosacea (Buhl et al., 2015). Hence,
      secukinumab could be effective against rosacea. This proposal is a proof-of-concept study to
      use secukinumab in open label design for moderate to severe papulopustular rosacea.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 21, 2017</start_date>
  <completion_date type="Actual">January 25, 2019</completion_date>
  <primary_completion_date type="Actual">January 25, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Papule/Pustule Count at Week 16</measure>
    <time_frame>Baseline, week 16</time_frame>
    <description>The total number of papules and pustules on the patient was assessed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Papule/Pustule Count at Week 12</measure>
    <time_frame>Baseline, week 12</time_frame>
    <description>The total number of papules and pustules on the patient was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Clinician's Global Severity Score for Rosacea at Week 16</measure>
    <time_frame>Baseline, week 16</time_frame>
    <description>Scale range: 0-4 (0=none to very mild; 1=mild; 2=moderate; 3=severe; 4=very severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Clinician's Global Erythema Assessment Score at Week 16</measure>
    <time_frame>Baseline, week 16</time_frame>
    <description>Scale range: 0-4 (0=none; 1=mild; 2=moderate; 3=significant; 4=severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Rosacea Quality of Life (RosaQoL) Score at Week 16</measure>
    <time_frame>Baseline, week 16</time_frame>
    <description>Scale range: 0-5 with greater scores denoting worse quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Count of Participants With ≥ Grade 3 Adverse Events</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Immune Infiltrates in Papulopustular Rosacea Lesions at Week 16</measure>
    <time_frame>Baseline, week 16</time_frame>
    <description>Immune infiltrates as assessed by immunohistochemistry, using a semi-quantitative grading scale for histological inflammation (scale range: 0-4, with 0-normal to 4-widespread inflammation).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Papulopustular Rosacea</condition>
  <arm_group>
    <arm_group_label>Secukinumab arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive secukinumab (7 doses over a 16-week study period).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Secukinumab</intervention_name>
    <description>Secukinumab 300 mg administered subcutaneously.</description>
    <arm_group_label>Secukinumab arm</arm_group_label>
    <other_name>Tremfya</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  moderate to severe papulopustular rosacea defined clinically using the grading system
             of Wilkin et al. (2004) as having at least ten lesions (either papules or pustules) on
             face at time of enrollment

          -  age 18 years or greater willing and able to understand and sign informed consent form

        Exclusion Criteria:

          -  known hypersensitivity to secukinumab

          -  topical or oral anti-rosacea medication usage for 28 days prior to enrollment

          -  active Crohn's disease, as secukinumab may exacerbate this disease

          -  active infection including tuberculosis, hepatitis B or C, human immunodeficiency
             virus

          -  participants with latent tuberculosis will need to have treatment initiated prior to
             starting study drug

          -  pregnant or lactating

          -  active and/or uncontrolled medical conditions that may interfere with study procedures
             or obscure rosacea assessment such as cutaneous lupus

          -  use of retinoids within past 3 months of enrollment

          -  use of antibiotics within 4 weeks of enrollment

          -  use of light based or laser treatment to face within 8 weeks of enrollment

          -  use of topical or systemic steroids within 4 weeks of enrollment

          -  acne conglobate, acne fulminans, chloracne, severe acne requiring systemic treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Chang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford Dermatology</name>
      <address>
        <city>Redwood City</city>
        <state>California</state>
        <zip>94603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Chang ALS, Raber I, Xu J, Li R, Spitale R, Chen J, Kiefer AK, Tian C, Eriksson NK, Hinds DA, Tung JY. Assessment of the genetic basis of rosacea by genome-wide association study. J Invest Dermatol. 2015 Jun;135(6):1548-1555. doi: 10.1038/jid.2015.53. Epub 2015 Feb 19.</citation>
    <PMID>25695682</PMID>
  </reference>
  <reference>
    <citation>Moustafa F, Hopkinson D, Huang KE, Feldman S. Prevalence of rosacea in community settings. J Cutan Med Surg. 2015 Mar-Apr;19(2):149-52. doi: 10.2310/7750.2014.14087. Epub 2015 Mar 11.</citation>
    <PMID>25775639</PMID>
  </reference>
  <reference>
    <citation>Blauvelt A, Prinz JC, Gottlieb AB, Kingo K, Sofen H, Ruer-Mulard M, Singh V, Pathan R, Papavassilis C, Cooper S; FEATURE Study Group. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2015 Feb;172(2):484-93. doi: 10.1111/bjd.13348. Epub 2014 Dec 11.</citation>
    <PMID>25132411</PMID>
  </reference>
  <reference>
    <citation>Buhl T, Sulk M, Nowak P, Buddenkotte J, McDonald I, Aubert J, Carlavan I, Déret S, Reiniche P, Rivier M, Voegel JJ, Steinhoff M. Molecular and Morphological Characterization of Inflammatory Infiltrate in Rosacea Reveals Activation of Th1/Th17 Pathways. J Invest Dermatol. 2015 Sep;135(9):2198-2208. doi: 10.1038/jid.2015.141. Epub 2015 Apr 7.</citation>
    <PMID>25848978</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>March 9, 2017</study_first_submitted>
  <study_first_submitted_qc>March 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2017</study_first_posted>
  <results_first_submitted>January 17, 2020</results_first_submitted>
  <results_first_submitted_qc>January 17, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 5, 2020</results_first_posted>
  <last_update_submitted>January 17, 2020</last_update_submitted>
  <last_update_submitted_qc>January 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Anne Chang</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosacea</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 15, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/31/NCT03079531/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Secukinumab Arm</title>
          <description>Secukinumab 300 mg administered subcutaneously (7 doses over a 16-week study period).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Attended ≥1 Post-baseline Visit</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants with at least one post-baseline visit were considered evaluable in this trial, and are included in the analysis for Baseline Characteristics.</population>
      <group_list>
        <group group_id="B1">
          <title>Secukinumab Arm</title>
          <description>Secukinumab 300 mg administered subcutaneously (7 doses over a 16-week study period).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56" lower_limit="50" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic/Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Two or More Races</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Papule/pustule count</title>
          <description>The total number of papules and pustules on the patient was assessed.</description>
          <units>papules and pustules</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.00" lower_limit="7.33" upper_limit="44.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Clinician's Global Severity Score for Rosacea</title>
          <description>Scale range: 0-4 (0=none to very mild; 1=mild; 2=moderate; 3=severe; 4=very severe).</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.83" lower_limit="1.33" upper_limit="3.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Clinician's Global Erythema Assessment Score</title>
          <description>Scale range: 0-4 (0=none; 1=mild; 2=moderate; 3=significant; 4=severe).</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.67" lower_limit="1.17" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Rosacea Quality of Life (RosaQoL) Score</title>
          <description>Scale range: 0-5 with greater scores denoting worse quality of life.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.48" lower_limit="2.57" upper_limit="4.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Immune Infiltrates in Papulopustular Rosacea Lesions</title>
          <description>Immune infiltrates as assessed by immunohistochemistry, using a semi-quantitative grading scale for histological inflammation (scale range: 0-4, with 0-normal to 4-widespread inflammation).</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.50" lower_limit="2.38" upper_limit="3.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Papule/Pustule Count at Week 16</title>
        <description>The total number of papules and pustules on the patient was assessed.</description>
        <time_frame>Baseline, week 16</time_frame>
        <population>Participants who completed through week 16 are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab Arm</title>
            <description>Secukinumab 300 mg administered subcutaneously (7 doses over a 16-week study period).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Papule/Pustule Count at Week 16</title>
          <description>The total number of papules and pustules on the patient was assessed.</description>
          <population>Participants who completed through week 16 are included in the analysis.</population>
          <units>papules and pustules</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.00" lower_limit="-17.6" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there would be no difference in papule/pustule count at baseline and after 16 weeks of secukinumab; the alternative hypothesis is that there would be a difference. Using an alpha=0.05 and power=0.80 (two sided test), the sample size needed would be 20. Assuming a dropout rate of 20%, 24 patients would be needed to achieve sufficient sample size.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>Wilcoxon signed rank test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Papule/Pustule Count at Week 12</title>
        <description>The total number of papules and pustules on the patient was assessed.</description>
        <time_frame>Baseline, week 12</time_frame>
        <population>Participants who completed through week 12 are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab Arm</title>
            <description>Secukinumab 300 mg administered subcutaneously (7 doses over a 16-week study period).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Papule/Pustule Count at Week 12</title>
          <description>The total number of papules and pustules on the patient was assessed.</description>
          <population>Participants who completed through week 12 are included in the analysis.</population>
          <units>papules and pustules</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.00" lower_limit="-16.66" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>Wilcoxon signed rank test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Clinician's Global Severity Score for Rosacea at Week 16</title>
        <description>Scale range: 0-4 (0=none to very mild; 1=mild; 2=moderate; 3=severe; 4=very severe).</description>
        <time_frame>Baseline, week 16</time_frame>
        <population>Participants who completed through week 16 are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab Arm</title>
            <description>Secukinumab 300 mg administered subcutaneously (7 doses over a 16-week study period).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Clinician's Global Severity Score for Rosacea at Week 16</title>
          <description>Scale range: 0-4 (0=none to very mild; 1=mild; 2=moderate; 3=severe; 4=very severe).</description>
          <population>Participants who completed through week 16 are included in the analysis.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" lower_limit="-0.83" upper_limit="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Wilcoxon signed rank test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Clinician's Global Erythema Assessment Score at Week 16</title>
        <description>Scale range: 0-4 (0=none; 1=mild; 2=moderate; 3=significant; 4=severe).</description>
        <time_frame>Baseline, week 16</time_frame>
        <population>Participants who completed through week 16 are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab Arm</title>
            <description>Secukinumab 300 mg administered subcutaneously (7 doses over a 16-week study period).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Clinician's Global Erythema Assessment Score at Week 16</title>
          <description>Scale range: 0-4 (0=none; 1=mild; 2=moderate; 3=significant; 4=severe).</description>
          <population>Participants who completed through week 16 are included in the analysis.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" lower_limit="-0.83" upper_limit="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.2</p_value>
            <method>Wilcoxon signed rank test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Rosacea Quality of Life (RosaQoL) Score at Week 16</title>
        <description>Scale range: 0-5 with greater scores denoting worse quality of life.</description>
        <time_frame>Baseline, week 16</time_frame>
        <population>Participants who completed through week 16 are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab Arm</title>
            <description>Secukinumab 300 mg administered subcutaneously (7 doses over a 16-week study period).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Rosacea Quality of Life (RosaQoL) Score at Week 16</title>
          <description>Scale range: 0-5 with greater scores denoting worse quality of life.</description>
          <population>Participants who completed through week 16 are included in the analysis.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.61" lower_limit="-1.53" upper_limit="-0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon signed rank test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Count of Participants With ≥ Grade 3 Adverse Events</title>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab Arm</title>
            <description>Secukinumab 300 mg administered subcutaneously (7 doses over a 16-week study period).</description>
          </group>
        </group_list>
        <measure>
          <title>Count of Participants With ≥ Grade 3 Adverse Events</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Immune Infiltrates in Papulopustular Rosacea Lesions at Week 16</title>
        <description>Immune infiltrates as assessed by immunohistochemistry, using a semi-quantitative grading scale for histological inflammation (scale range: 0-4, with 0-normal to 4-widespread inflammation).</description>
        <time_frame>Baseline, week 16</time_frame>
        <population>Participants who contributed skin biopsies at both week 0 and week 16 are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab Arm</title>
            <description>Secukinumab 300 mg administered subcutaneously (7 doses over a 16-week study period).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Immune Infiltrates in Papulopustular Rosacea Lesions at Week 16</title>
          <description>Immune infiltrates as assessed by immunohistochemistry, using a semi-quantitative grading scale for histological inflammation (scale range: 0-4, with 0-normal to 4-widespread inflammation).</description>
          <population>Participants who contributed skin biopsies at both week 0 and week 16 are included in the analysis.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" lower_limit="-0.25" upper_limit="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.56</p_value>
            <method>Wilcoxon signed rank test</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>16 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Secukinumab Arm</title>
          <description>Secukinumab 300 mg administered subcutaneously (7 doses over a 16-week study period).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hearing impaired</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Flu like symptoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Skin or nail infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Sinus pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Sinus disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Allergic rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Rash (eczema)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Anne Lynn Chang, MD</name_or_title>
      <organization>Stanford University</organization>
      <phone>650-723-6316</phone>
      <email>alschang@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

